Cerenome (CNSY) vs NeuroOne Medical Technologies (NMTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroOne Medical Technologies (NMTC) has outperformed Cerenome (CNSY) over the past year, losing 82.7% versus a loss of 90.5%. Over five years, NMTC leads with a -94.0% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.6 million vs $10.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | NMTC |
|---|---|---|
| Share price | $1.93 | $1.12 |
| Market cap | $14.65M | $10.20M |
| 1-day change | +7.82% | +3.70% |
| YTD return | -85.96% | -76.25% |
| 1-year return | -90.45% | -82.69% |
| 5-year return | -99.73% | -94.00% |
| EPS (TTM) | $-3.36 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $6.42 |
| 52-week low | $1.49 | $0.962 |
| Distance from 52-week high | -89.84% | -82.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1337.82% | +549.11% |
| Average volume | 121.12K | 339.60K |
| Shares outstanding | 7.59M | 9.11M |
| Employees | 28 | 18 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About NeuroOne Medical Technologies
NMTC stock →NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Health Care · Medical/Dental Instruments · 18 employees
CNSY vs NMTC FAQ
Which is bigger, Cerenome or NeuroOne Medical Technologies?
Cerenome (CNSY) is larger, with a market capitalization of $14.65M compared with $10.20M for NeuroOne Medical Technologies (NMTC).
Which stock has performed better over the past year, CNSY or NMTC?
NMTC returned -82.69% over the past 12 months, compared with -90.45% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and NeuroOne Medical Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.